Therefore, we counted the proportion of lung cancer patients with low expression of PTEN and high expression of ELF3 as a percentage of all lung adenocarcinoma patients recorded in two databases, which were 27.3 and 29%, respectively (Fig. 3A). Here, ELF3 is linked to lung adenocarcinoma.